Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Proteostasis raises $45 million

This article was originally published in Scrip

Executive Summary

Proteostasis Therapeutics, a US-based drug discovery company, has raised $45 million in a series A financing round to develop proteostasis regulator drugs as novel therapies for multiple genetic and degenerative disorders associated with protein homeostasis deficiencies. The funding will be used for conditions such as emphysema, type 2 diabetes, Alzheimer's disease and Huntington's disease. Proteostasis secured initial funding more than a year ago. This series A round is designed to support the company's strategy to advance proprietary compounds into the clinic, Dr Christopher Mirabelli, managing director of HealthCare Ventures and chairman of Proteostasis' board of directors, said. The financing was led by HealthCare Ventures, Fidelity Biosciences, New Enterprise Associates, Novartis Option Fund and Genzyme Ventures. Proteostasis has also appointed Dr Stephen Knight, managing partner of Fidelity Biosciences, Dr James Barrett, general partner at New Enterprise Associates, Dr Lauren Silverman, managing director of Novartis Option Fund, and Dr Alan Walts, managing director of Genzyme Ventures, to its board of directors.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC000178

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel